BioMarin Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw unusually large options trading activity on Tuesday. Stock investors purchased 3,961 call options on the stock. This is an increase of 228% compared to the average volume of 1,206 call options.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $55.66 on Wednesday. The firm’s fifty day moving average price is $60.24 and its 200 day moving average price is $58.45. BioMarin Pharmaceutical has a 1-year low of $49.26 and a 1-year high of $70.98. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. The firm has a market cap of $10.77 billion, a price-to-earnings ratio of -556.60, a price-to-earnings-growth ratio of 0.63 and a beta of 0.21.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.28. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.59%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the prior year, the firm earned $0.12 EPS. BioMarin Pharmaceutical’s quarterly revenue was up 32.0% on a year-over-year basis. On average, sell-side analysts expect that BioMarin Pharmaceutical will post 2.59 EPS for the current year.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Third-quarter revenue rose 32% year over year to about $1.025 billion, in line with estimates, while non-GAAP EPS of $0.23 beat consensus expectations for a loss. Metabolic and skeletal-condition sales increased 44% and 12%, respectively. BioMarin Q3 results
• Positive Sentiment: BioMarin added an investigational Fabry-disease asset to its pipeline, while VOXZOGO for hypochondroplasia has an FDA action date of May 30, 2027—potential longer-term growth catalysts. BioMarin Q3 results
• Neutral Sentiment: Analyst views were mixed: Morgan Stanley maintained an Overweight rating despite trimming its target to $119, while HC Wainwright reaffirmed Neutral with a $60 target. Morgan Stanley rating HC Wainwright rating
• Negative Sentiment: BioMarin’s 2026 EPS outlook of $2.80–$3.10 is below the $3.32 consensus. Revenue guidance of $3.8–$3.9 billion also falls short of the $3.9 billion estimate at the low end; the company cited uncertainty around order timing and two acquired IPR&D charges. 2026 guidance update
• Negative Sentiment: RBC lowered its price target from $62 to $60 and kept a Sector Perform rating. The target reductions from RBC and Morgan Stanley temper the positive implications of the quarterly beat. RBC rating

Analysts Set New Price Targets

A number of brokerages have recently commented on BMRN. Weiss Ratings cut shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 18th. Jefferies Financial Group increased their target price on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a “buy” rating in a research note on Monday, August 31st. HC Wainwright reissued a “neutral” rating and set a $60.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday. Oppenheimer dropped their price target on BioMarin Pharmaceutical from $97.00 to $94.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.96.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BMRN. Primecap Management Co. CA purchased a new position in shares of BioMarin Pharmaceutical in the 2nd quarter valued at about $811,962,000. Caisse de depot et placement du Quebec acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at about $70,749,000. Bank of New York Mellon Corp purchased a new stake in BioMarin Pharmaceutical during the second quarter worth about $66,107,000. Edmond DE Rothschild Holding S.A. purchased a new stake in BioMarin Pharmaceutical during the second quarter worth about $39,312,000. Finally, Palo Alto Investors LP purchased a new stake in BioMarin Pharmaceutical during the second quarter worth about $39,068,500. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.